Tempus AI マネジメント
マネジメント 基準チェック /24
現在、CEO に関する十分な情報がありません。
主要情報
Eric Lefkofsky
最高経営責任者
US$41.5m
報酬総額
| CEO給与比率 | 1.89% |
| CEO在任期間 | no data |
| CEOの所有権 | 23.3% |
| 経営陣の平均在職期間 | 4.6yrs |
| 取締役会の平均在任期間 | 5.2yrs |
経営陣の近況
Recent updates
分析記事 • Jun 19
Tempus AI (TEM) Stock Could Be 22.9% Undervalued After ECG AF Validation
Tempus AI (TEM) is back in focus after publishing a multi site validation of its FDA cleared ECG AF software, which predicts one year atrial fibrillation or flutter risk in older adults without prior AF. See our latest analysis for Tempus AI. Tempus AI’s shares have picked up momentum recently, with a 1 month share price return of 10.81% and a 7 day gain of 6.32%. However, the year to date share price return is still down 18.47% and the 1 year total shareholder return has declined 25.57%...
ナラティブの更新 • Jun 13
TEM: FDA Progress And Data Platforms Will Drive Future Oncology Demand
Tempus AI's analyst price targets have shifted lower to around $66.53, reflecting a mix of downward revisions and more cautious views on long term monetization from several firms, even as others acknowledge the company's differentiated data offering. Analyst Commentary Recent research paints a mixed picture around Tempus AI, with views split on how quickly the company can translate its differentiated data assets into predictable cash flows and what that should mean for valuation.
新しいナラティブ • Jun 09
An Overlooked AI Play That’s Quietly Building a Healthcare Data Empire
Tempus AI isn't simply an AI software business (not another ChatBot). It's building a healthcare data platform where diagnostics, genomic testing, clinical data, and AI applications reinforce each other through a powerful network effect.Seeking Alpha • Jun 09
Tempus AI: A Unique AI Business Model With Asymmetric Upside
Summary Tempus AI is rated Strong Buy, leveraging a unique data moat and network effect in healthcare AI. TEM's Diagnostics and Data & Applications segments drive robust 36% YoY revenue growth, with expanding gross margins and deepening pharma partnerships. Massive proprietary datasets (45M+ de-identified records, 500+ PB) underpin AI tools, SaaS revenue, and cross-selling opportunities, creating high barriers to entry. Key risks include continued unprofitability, $1.3B debt, high short interest (20%), and regulatory sensitivity, but profitability and AI adoption could trigger a short squeeze. Read the full article on Seeking Alphaナラティブの更新 • May 30
TEM: FDA Approvals And Partnerships Will Support Future Oncology Data Demand
Narrative Update The average analyst price target for Tempus AI has moved lower by several dollars to reflect a mix of reduced targets from H.C. Wainwright, BTIG, Baird, Guggenheim, and Morgan Stanley, partially offset by modest upward revisions and an upgrade from TD Cowen and TD Securities. Analysts are incorporating recent results, updated models, and ongoing partnership activity into their assessments.ナラティブの更新 • May 13
TEM: Data Partnerships And Backlog Will Support Future Oncology Data Upside
Tempus AI's analyst price target is now $67.20, down from $72.40, as analysts adjust their models to reflect more moderate revenue growth assumptions and mixed recent price target revisions across the Street. Analyst Commentary Recent research on Tempus AI shows a mix of optimism and caution as analysts update their models, adjust price targets, and refine views following Q4 results and new coverage initiations.ナラティブの更新 • Apr 28
TEM: Data Partnerships And Backlog Will Support Future Oncology Data Monetization
Analysts have slightly reduced the blended price target on Tempus AI to $72.40. This reflects updated models around revenue growth, profit margins and P/E assumptions after a mix of target cuts and increases across recent research, including responses to Q4 results and ongoing partnership momentum.ナラティブの更新 • Apr 13
TEM: Data Partnerships And Backlog Will Support Future Precision Oncology Leadership
Narrative Update on Tempus AI The updated analyst price target for Tempus AI moves to $72.73 from $77.93, as analysts factor in slightly higher discount rates and a lower future P/E multiple. They still point to ongoing partnerships and data backlog as key supports for the long term story.ナラティブの更新 • Mar 26
TEM: Data Partnerships And Backlog Will Drive Future Precision Oncology Execution
Analysts report a modestly adjusted fair value estimate of $77.93 per share for Tempus AI, reflecting mixed price target revisions that weigh the impact of new partnerships and data backlog strength against updated post Q4 models and views on visibility in parts of the business. Analyst Commentary Recent Street research on Tempus AI reflects a split view, with some focusing on growth potential in precision medicine and data, and others emphasizing execution risks and visibility in parts of the business.ナラティブの更新 • Mar 11
TEM: Data Partnerships And Backlog Will Support Future Precision Oncology Upside
Our updated view trims Tempus AI's implied fair value from about $86.71 to $77.93 per share, reflecting analysts' mixed price target revisions after Q4. Some highlight expanding pharma and academic partnerships and a large data backlog, while others factor in model updates, valuation resets, and questions around data upside and Ambry.
新しいナラティブ • Mar 04
Heavy AI Infrastructure And Rising Costs Will Pressure Data Economics Yet Eventually Support Upside
Catalysts About Tempus AI Tempus AI provides AI driven molecular diagnostics and data products to support clinical decision making and drug development. What are the underlying business or industry changes driving this perspective?ナラティブの更新 • Feb 24
TEM: Precision Oncology And AI Biomarkers Will Support Future Upside Potential
Narrative update on Tempus AI The updated analyst price target for Tempus AI has edged down by about $1 to reflect slightly lower fair value and profit margin assumptions, even as analysts highlight the company's role in precision oncology diagnostics and AI-enabled healthcare data services as a key factor in its long term revenue growth outlook. Analyst Commentary Recent research coverage on Tempus AI highlights both enthusiasm for its role in precision oncology and AI driven healthcare data, and a set of execution and valuation questions that investors are watching closely.
新しいナラティブ • Feb 18
Genomics And AI Data Licensing Will Transform Long Term Oncology Outcomes
Catalysts About Tempus AI Tempus AI operates a genomics and data platform focused on Oncology and related clinical insights. What are the underlying business or industry changes driving this perspective?ナラティブの更新 • Feb 10
TEM: AI Biomarker Advancements In Oncology Will Drive Future Returns
Analysts have nudged their price target on Tempus AI higher to about US$87.92, citing slightly stronger modeled revenue growth, profit margins, and a marginally lower future P/E assumption in their updated forecasts. What's in the News Tempus reported new clinical validation data for its Immune Profile Score test, indicating that the algorithmic biomarker more accurately predicts outcomes for patients receiving immune checkpoint inhibitors than several conventional biomarkers across multiple metastatic solid tumor cohorts.ナラティブの更新 • Jan 26
TEM: Oncology Data Collaborations And AI Pathology Will Drive Future Returns
Analysts have kept their fair value estimate for Tempus AI steady at about US$87.92 per share, with only very small tweaks to inputs like discount rate, revenue growth, profit margins and future P/E assumptions supporting an unchanged overall target. What's in the News Tempus AI launched Paige Predict, a suite of AI pathology tools that analyze H&E whole slide images to help predict the likelihood of 123 biomarkers and oncogenic pathways across 16 cancer types, with results delivered alongside clinical reports to physicians (Product-Related Announcements).ナラティブの更新 • Jan 12
TEM: Oncology Data Collaborations Will Drive Future Returns Despite Slightly Higher Risk
Analysts have trimmed their fair value estimate for Tempus AI by about US$1.00, reflecting slightly higher discount rate assumptions as well as marginally adjusted revenue growth, profit margin, and future P/E inputs. What's in the News Tempus AI plans to present ten research abstracts at the 2025 San Antonio Breast Cancer Symposium, focusing on multimodal real world data, risk stratification for CDK4/6 inhibitor plus endocrine therapy, and tumor microenvironment signatures in hormone receptor positive, HER2 negative metastatic breast cancer (Key Developments).ナラティブの更新 • Dec 25
TEM: Future Oncology Data Partnerships Will Drive Profits Despite Modestly Higher Risk
Analysts have modestly reduced their price target on Tempus AI by approximately 3 dollars, reflecting slightly higher perceived risk and marginally slower long term growth expectations, partly offset by improved profit margin and a lower projected future price to earnings multiple. What's in the News Tempus AI will present ten research abstracts at the 2025 San Antonio Breast Cancer Symposium, showcasing multimodal real world data approaches to better stratify metastatic breast cancer patients and identify responders to CDK4/6 inhibitors (Key Developments).ナラティブの更新 • Dec 11
TEM: Future Profit Margins Will Expand As Federal Oncology Program Catalysts Mature
Narrative Update on Tempus AI Analyst Price Target Analysts have slightly raised their price target on Tempus AI to approximately 91 dollars and 42 cents from 91 dollars, citing a marginally lower perceived risk profile and stable long term growth and profitability assumptions. What's in the News Tempus received FDA 510(k) clearance for its RNA based xR IVD sequencing assay, expanding its toolkit for drug development partners and strengthening its position as a comprehensive precision oncology platform (FDA filing).ナラティブの更新 • Nov 26
TEM: Future Profit Margins Will Expand With AI-Powered Clinical Partnerships
Analysts have revised Tempus AI's price target upwards from $87.17 to $91.00, citing improved profit margin projections and a significantly lower anticipated future price-to-earnings ratio. What's in the News Tempus AI and the Institute for Follicular Lymphoma Innovation (IFLI) launched their first collaborative research study with a non-profit foundation to create a comprehensive, multi-omic dataset for follicular lymphoma.ナラティブの更新 • Nov 09
TEM: Revenue Will Accelerate With New Real-World Data Partnership
Analysts have raised their price target for Tempus AI from $82.50 to $87.17, citing shifts in expected growth and profitability as supporting factors for the updated valuation. What's in the News Tempus AI announced six new abstracts accepted for presentation at the SITC Annual Meeting 2025, highlighting advances in multi-omic algorithms and biomarkers for rare and advanced cancers (Product-Related Announcements).ナラティブの更新 • Oct 26
Advances In Precision Medicine And AI Will Reshape Cancer Care Futures
Analysts have raised their price target for Tempus AI from $77.55 to $82.50, citing stronger confidence in revenue growth and profitability projections. What's in the News Tempus AI and Whitehawk Therapeutics announced a multi-year collaboration to use Tempus' real-world dataset to advance biomarker-driven research and enhance oncology clinical trial design.ナラティブの更新 • Oct 12
Expanding Genomic Testing And AI Will Build Lasting Healthcare Value
Tempus AI's fair value estimate has been raised by analysts from $74.82 to $77.55 per share. This reflects optimism about improved revenue growth and updated market outlooks.分析記事 • Oct 09
After Leaping 29% Tempus AI, Inc. (NASDAQ:TEM) Shares Are Not Flying Under The Radar
Despite an already strong run, Tempus AI, Inc. ( NASDAQ:TEM ) shares have been powering on, with a gain of 29% in the...ナラティブの更新 • Sep 28
Expanding Genomic Testing And AI Will Build Lasting Healthcare Value
Tempus AI’s valuation has become more expensive with a higher forward P/E and declining net profit margin, leading to only a marginal increase in the consensus analyst price target to $74.82. What's in the News Tempus AI received FDA 510(k) clearance for its RNA-based Tempus xR IVD device and updated Tempus Pixel cardiac imaging platform, expanding its diagnostics and AI imaging capabilities.ナラティブの更新 • Sep 13
Expanding Genomic Testing And AI Will Build Lasting Healthcare Value
Tempus AI’s consensus future P/E and discount rate held steady with minimal movement, supporting only a slight upward revision in fair value from $72.73 to $73.45. What's in the News Tempus AI received FDA 510(k) clearance for its updated Tempus Pixel, an AI-powered cardiac imaging platform, which now enables generation of T1 and T2 inline maps for enhanced cardiac MR image analysis, supporting more precise and efficient diagnostics.ナラティブの更新 • Aug 27
Expanding Genomic Testing And AI Will Build Lasting Healthcare Value
Tempus AI's slightly higher consensus price target reflects a significant increase in its future P/E ratio despite a decline in net profit margin, resulting in a new fair value estimate of $71. What's in the News Tempus AI filed a $500 million follow-on equity offering of Class A Common Stock via an at-the-market transaction and raised its full-year 2025 revenue guidance to approximately $1.26 billion, representing ~82% annual growth.分析記事 • Aug 15
Tempus AI, Inc. (NASDAQ:TEM) Looks Just Right With A 28% Price Jump
Tempus AI, Inc. ( NASDAQ:TEM ) shareholders would be excited to see that the share price has had a great month, posting...新しいナラティブ • Jun 15
AstraZeneca And Pathos Partnership Will Expand Precision Medicine
Pharma partnerships and the shift toward AI-driven precision medicine are fueling strong, high-margin revenue growth and expanding Tempus' competitive opportunities.CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$303m |
| Dec 31 2025 | US$41m | US$783k | -US$245m |
| Sep 30 2025 | n/a | n/a | -US$203m |
| Jun 30 2025 | n/a | n/a | -US$199m |
| Mar 31 2025 | n/a | n/a | -US$720m |
| Dec 31 2024 | US$29m | n/a | -US$745m |
| Sep 30 2024 | n/a | n/a | -US$801m |
| Jun 30 2024 | n/a | n/a | -US$790m |
| Mar 31 2024 | n/a | n/a | -US$293m |
| Dec 31 2023 | US$2k | n/a | -US$254m |
| Sep 30 2023 | n/a | n/a | -US$276m |
| Dec 31 2022 | US$2k | n/a | -US$334m |
報酬と市場: Ericの 総報酬 ($USD 41.50M ) は、 US市場 ($USD 8.43M ) の同規模の企業の平均を上回っています。
報酬と収益: Ericの報酬は増加しましたが、会社は利益を上げていません。
CEO
Eric Lefkofsky (56 yo)
no data
在職期間
US$41,495,833
報酬
Mr. Eric P. Lefkofsky, J.D., is Co-Founder & Chairman of Pathos AI, Inc. Mr. Lefkofsky was Executive Director of Pathos AI, Inc. Mr. Eric P. Lefkofsky is Co-Founder of Groupon, Inc. from November 2023. He...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | no data | US$41.50m | 23.31% $ 2.0b | |
| Chief Financial Officer | 5.2yrs | US$6.36m | 0.010% $ 857.5k | |
| Executive VP and Chief Administrative & Legal Officer | 6yrs | US$4.55m | 0.014% $ 1.2m | |
| General Counsel | less than a year | US$6.58m | 0.011% $ 943.4k | |
| Chief Executive Officer of Data & Apps | less than a year | US$11.60m | 0.42% $ 35.7m | |
| Chief Accounting Officer | no data | データなし | 0.011% $ 903.0k | |
| Chief Technology Officer | no data | データなし | データなし | |
| Chief Scientific Officer | 3.7yrs | データなし | データなし | |
| Vice President of Investor Relations & Competitive Intelligence | no data | データなし | データなし | |
| Senior VP & Head of Corporate Development | 5.4yrs | データなし | データなし | |
| Chief People Officer | 4.1yrs | データなし | データなし | |
| Senior Vice President of External Affairs | 6.8yrs | データなし | データなし |
4.6yrs
平均在職期間
48yo
平均年齢
経験豊富な経営陣: TEMの経営陣は 経験豊富 であると考えられます ( 4.6年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | no data | US$41.50m | 23.31% $ 2.0b | |
| Independent Director | 8.8yrs | US$199.67k | 0.059% $ 5.1m | |
| Independent Director | 7.4yrs | US$187.17k | 0.041% $ 3.5m | |
| Independent Director | 2.3yrs | US$187.25k | 0.0060% $ 515.5k | |
| Independent Director | 7.4yrs | US$187.17k | 0.012% $ 993.3k | |
| Independent Director | 6.7yrs | US$187.17k | 0.0082% $ 708.0k | |
| Independent Director | 5.2yrs | US$188.18k | 0.0077% $ 665.9k | |
| Independent Director | 5.7yrs | US$187.17k | 0.0089% $ 768.1k | |
| Member of Advisory Board | 1.2yrs | データなし | データなし | |
| Independent Director | 5.2yrs | US$187.17k | 0.013% $ 1.1m | |
| Advisory Board Member | 1.2yrs | データなし | データなし | |
| Member of Advisory Board | 1.2yrs | データなし | データなし |
5.2yrs
平均在職期間
62yo
平均年齢
経験豊富なボード: TEMの 取締役会 は 経験豊富 であると考えられます ( 5.2年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/23 12:17 |
| 終値 | 2026/06/23 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Tempus AI, Inc. 17 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。22
| アナリスト | 機関 |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Michael Ryskin | BofA Global Research |
| Mark Massaro | BTIG |